The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

smartinsulin.com

Stage

Acquired | Acquired

Total Raised

$8.85M

Valuation

$0000 

About SmartCells

SmartCells is developing a modified version of insulin for diabetics.

SmartCells Headquarter Location

100 Cummings Center Suite 419E

Beverly, Massachusetts, 01915,

United States

978-927-4246

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing SmartCells

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SmartCells is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,750 items

SmartCells Patents

SmartCells has filed 20 patents.

The 3 most popular patent topics include:

  • Amines
  • Carbohydrate chemistry
  • Carbohydrates
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/18/2017

9/3/2019

Ketones, Ureas, Amines, Organic reactions, Organic chemistry

Grant

Application Date

8/18/2017

Grant Date

9/3/2019

Title

Related Topics

Ketones, Ureas, Amines, Organic reactions, Organic chemistry

Status

Grant

Latest SmartCells News

MelliCell Appoints Dr. Todd Zion, Founder of SmartCells and Akston Biosciences, to Advisory Board

Jul 8, 2021

07/08/2021 | 03:08pm EDT Message : *Required fields NEWTON, Mass., July 8, 2021 /PRNewswire/ -- MelliCell, a startup dedicated to reversing obesity and type 2 diabetes by targeting fat cells, has announced today the close of its pre-seed round and the appointment of Todd Zion, Ph.D., President and CEO of Akston Biosciences, as a member of its advisory board. Dr. Zion brings business, diabetes, and bioscience expertise to the board. Prior to his current role at Akston Biosciences, Dr. Zion was the founder and CEO of SmartCells, where he led the development of the first glucose-regulated insulin formulation, SmartInsulin. Dr. Zion took the diabetes-focused company from founding in 2003 to an acquisition in 2010. "Dr. Zion is a wonderful addition to our advisory board as we pursue our goal to cure diabetes and obesity," said Dr. Prince Nnah, CEO of MelliCell. "Our company was founded at the beginning of the pandemic, and the devastation left in the wake of COVID-19 has made it clear that the need to address metabolic diseases is more urgent than ever before. We are grateful to all of our investors and advisors, like Dr. Zion, who support our efforts to get to the root of obesity and diabetes." Since its inception in 2020, MelliCell's unique approach to tackling metabolic diseases has garnered excitement and support from industry leaders and investors. Joined in its most recent funding round was Kensington Capital and other angel investors. MelliCell's next funding round, a series seed, is planned for the third quarter this year. "MelliCell has a vision and a novel approach that could revolutionize the treatment of the disease," said Dr. Zion. "I am thrilled to be in this role supporting them." About MelliCell Inc. is a biotechnology company founded in 2020 to cure obesity and type 2 diabetes. MelliCell uses proprietary technology to recreate human fat cells and test therapies for the diseases. The company is in its early funding stages and is interested in investing and partnership opportunities to further their mission to develop therapeutics that solve diabetes and obesity. If you are interested in learning more or joining their cause, please contact Prince Nnah at Prince@MelliCell.com . For media requests, please contact Michal@MelliCell.com . For the most up to date information about MelliCell's efforts to cure diabetes and obesity, find them on LinkedIn at linkedin.com/mellicell  or visit www.mellicell.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/mellicell-appoints-dr-todd-zion-founder-of-smartcells-and-akston-biosciences-to-advisory-board-301328263.html SOURCE MelliCell Inc

You May Also Like

R
RevDia

RevDia is a provider of a therapeutic diagnostic testing platform. The company's diagnostic testing platform is designed to detect an active periodontal infection. Its technology is intended to measure elevated levels of slgA in saliva that is specific to Aa and Pg virulence proteins, an attribute displayed by bacteria when it becomes pathogenic during an active infection.

Protemix Logo
Protemix

Protemix is a biopharmaceutical company that discovers, develops and commercializes drug therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and complications.

S
Sanomune

Sanomune is a private biotech start-up focused on neurological and autoimmune diseases. The company's technology is based on the repurposing of a safe, oral biological to treat large market indications. Sanomune's lead product, SAN-61, is a potential first-in-class treatment targeting the dual hallmark pathologies of Alzheimer's (AD): amyloid beta plaque deposition and the formation of neurofibrillary tangles. No other known therapy can effectively target both aspects of the disease. Sanomune's pipeline also includes products for rheumatoid arthritis (RA) multiple sclerosis (MS), stroke and diabetes. One patent has issued and six others have been filed. Sanomune is developing a recombinant form of its core biological as well as a nasal delivery device. With a $1.1 million Series A financing, Sanomune has secured compelling efficacy data, a strong IP position and has submitted, just recently, for regulatory approval to begin Phase II trials for AD and RA.

E
Emiliem

Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.

Aphios Logo
Aphios

Biopharmaceutical company developing enabling technology platforms and enhanced natural therapeutics for certain infectious diseases, cancers and CNS disorders. Ehanced therapeutics include small molecules from medicinal plants and marine organisms, and improved drug delivery formulations of protein macromolecules and hydrophobic anticancer drugs.

W
WesaGen

WesaGen is a biopharmaceutical company founded by Dr.Mustapha Abdelouahed, Ph.D., with expertise in Immunology, Hemostasis, Coagulation, Cell & Molecular Biology of Vessels, and Dr. Jack Lawler, Ph.D., Professor at Harvard Medical School. WesaGen is engaged in the near-term development of technologies to diagnose type 2 heparin-induced thrombocytopenia (or HIT, a life-threatening condition); the development of a line of and potent anti-angiogenic therapeutic drugs to treat cancer; and research and development based on a new nanoscale drug delivery platform technology.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.